BioSpace News Archive

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary.

Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”).

Stryker (NYSE:SYK) announced today that its Board of Directors intends to nominate Rachel Ruggeri for election to the Company’s Board of Directors at Stryker’s 2024 Annual Meeting of Shareholders, which is expected to be held on May 9, 2024.

The global biosimilar market size was estimated at USD 25,125.36 million in 2022 and is projected to surpass around USD 1,26,019.67 million by 2032, growing at a CAGR of 17.6% between 2023 and 2032.

Lexaria Bioscience Corp. announces that the Company’s anticipated submission of an Investigational New Drug application with the U.S. Food and Drug Administration for its planned U.S. Phase 1b Hypertension Clinical Trial is expected to be filed within approximately 45 days.

Cosmos Health Inc. announced an agreement with Cloudpharm PC to acquire the rights arising from the patent filed with the World Intellectual Property Organization, under reference code PCT/EP2023/071865.

Camino Pharma, LLC announced that its co-founder and CSO, Reto Gadient, Ph.D., has been awarded a two-year, $1.97M grant by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number U43AA031388 and is the Principal Investigator on the grant.

GIE Medical, a clinical stage company developing solutions for patients suffering from benign stricture(s) of the esophagus or bowel, announced today that enrollment has begun in its Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture - Esophagus (PATENT-E) study.

The global AI in drug discovery market size will hit around USD 15.44 billion by 2032 and growing at a CAGR of 29.66% from 2023 to 2032.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.